Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 4, 2005, Pages 601-608

  Ward, Alexandra ^a   O'Brien, Judith ^b   Salas, Maribel ^b  

^a CARO RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Acarbose; Cost effectiveness; Diabetes; Economic models; Economics; Hypoglycaemic drugs; Metformin; Nateglinide; Pharmacoeconomics; Pioglitazone; Repaglinide; Rosiglitazone; Sulfonylureas

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

COST EFFECTIVENESS ANALYSIS; DIET; EXERCISE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; LIFESTYLE; LIVER TOXICITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; UNITED KINGDOM; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 18144378841     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.4.601     Document Type: Review

References (46)

1. AMERICAN DIABETES ASSOCIATION: Economic costs of diabetes in the US in 2002. Diabetes Care (2003) 26(3):917-932.
2. WILLIAMS R, VAN GAAL L, LUCIONI C: CODE-2 Advisory Board assessing the impact of complications on the costs of type II diabetes. Diabetologia (2002) 45(7):S13-S17.
3. UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
4. MCINTOSH A, HUTCHINSON A, HOME PD et al.: Clinical guidelines and evidence review for type 2 diabetes: blood glucose management. Sheffield: Sc HARR, University of Sheffield (2001).
5. FELD S: AACE Diabetes guidelines. Endocrine Practice (2000) 6:43-67.
6. MATTHEWS DR, CULL CA, STRATTON IM et al.: UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabetic Med. (1998) 15:297-303.
7. TURNER RC, CULL CA, FRIGHI V, HOLAMN RR, UKPDS GROUP: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA (1999) 281:2005-2012.
8. LARSEN DL, CANNON W, TOWNER S: Longitudinal assessment of a diabetes care management system in an integrated health network. J. Managed Care Pharm. (2003) 9(6):552-558.
9. WILD S, ROGLIC G, GREEN A, SICREE R, KING H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27(5):1047-1053.
10. HARRIS MI, KLEIN R, WELBORN TA, KNUIMAN MW: Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care (1992) 15(7):815-819.
11. UBINK-VELTMAAT LJ, BILO HJ, GROENIER KH, HOUWELING ST, RISCHEN RO, MEYBOOM-DE JONG B: Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-I). Eur. J. Epidemiol. (2003) 18(8):793-800.
12. RISTE L, KHAN F, CRUICKSHANK K: High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity; or 21st century Europe? Diabetes Care (2001) 8:1377-1383.
13. HIPPISLEY-COX J, O'HANLON S, COUPLAND C: Association of deprivation, ethnicity, and sex with quality indicators for diabetes: population based survey of 53,000 patients in primary care. Br. Med. J. (2004) 329(7477):1267-1269.
14. CDC: Prevalence of diabetes and impaired fasting glucose in adults. United States 1999-2000. MMWR (2003) 52(35):833-837.
15. HAFFNER SM, LEHTO S, RONNEMAA T, PYORALA K, LAAKSO M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. (1998) 339(4):229-234.
16. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Self-reported heart disease and stroke among adults with and without diabetes-United States, 1999-2001. MMWR Morb. Mortal. Wkly Rep. (2003) 52(44):1065-1070.
17. FONG DS, AIELLO L, GARDNER T et al.: Diabetic Renitopathy. Diabetes Care (2003) 26(Suppl. 1):S99-S102.
18. U.K. PROSPECTIVE DIABETES STUDY GROUP: Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care (1999) 22(7):1125-1136.
19. GRAY A, RAIKOU M, MCGUIRE A et al.: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. Br. Med. J. (2000) 320(7246):1373-1378.
20. UK PROSPECTIVE DIABETES STUDY GROUP: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. Br. Med. J. (1998) 317(7160):720-726.
21. GRAY A, CLARKE P, RAIKOU M et al.: An economic evaluation of atenolol versus captopril in patients with type 2 diabetes (UKPDS 54). Diabet. Med. (2001) 18(6):438-444.
22. GRAY A, CLARKE P, FARMER A, HOLMAN R: United Kingdom Prospective Diabetes Study (UKPDS) Group. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). Br. Med. J. (2002) 325(7369):860.
23. HOOD SC, ANNEMANS L, RUTTEN-VAN MOLKEN M: A short term cost-effectiveness model for oral antidiabetic medicines in Europe. Pharmacoeconomics (1998) 13(3):317-326.
24. RAMSDELL JW, GROSSMAN JA, STEPHENS JM, BOTTEMAN MF, AROCHO R: A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose. Am. J. Manag. Care (1999) 5(8):1007-1024.
25. RAMSDELL JW, BRAUNSTEIN SN, STEPHENS JM, BELL CF, BOTTEMAN MF, DEVINE ST: Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. Pharmacoeconomics (2003) 21(11):819-837.
26. CARO J, SALAS M, O'BRIEN J, ISHAK K, SUNG J, RAGGIO G: Modeling the efficiency of reaching a target intermediate end point: a case study in type 2 diabetes in the United States. Value in Health (2004) 7(1):17-25.
27. PALMER AJ, SENDI PP, SPINAS GA: Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweiz. Med. Wochenschr. (2000) 130(27-28):1034-1040.
28. HENRIKSSON F: Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. Pharmacoeconomics (2002) 20(Suppl. 1):43-53.
29. BROWN JB, RUSSELL A, CHAN W, PEDULA K, AICKIN M: The global diabetes model: user friendly version 3.0. Diabetes Res. Clin. Pract. (2000) 50(Suppl. 3):S15-S46.
30. BAGUST A, HOPKINSON PK, MAIER W, CURRIE CJ: An economic model of the long-term health care burden of type II diabetes. Diabetologia (2001) 44(12):2140-2155.
31. SALAS M, WARD A, CARO J: Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin. Ther. (2002) 24(10):1690-1705.
32. COYLE D, PALMER AJ, TAM R: Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics (2002) 20(Suppl. 1):31-42.
33. CDC DIABETES COST-EFFECTIVENESS GROUP: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA (2002) 287(19):2542-2551.
34. EARNSHAW SR, RICHTER A, SORENSEN SW et al.: Optimal allocation of resources across four interventions for type 2 diabetes. Med. Decis. Making (2002) 22(5 Suppl.):S80-S91.
35. COYLE D, LEE KM, O'BRIEN BJ: The role of models within economic analysis: focus on type 2 diabetes mellitus. Pharmacoeconomics (2002) 20(Suppl. 1):11-19.
36. RAIKOU M, MCGUIRE A: The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics (2003) 21(8):543-564.
37. CLARKE P, GRAY A, HOLMAN R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med. Decis. Making (2002) 22:340-349.
38. Review of completed technology appraisals 2000/2001. Item 3 National Institute of Clinical Excellence Annual Public Meeting, 18 July 2001.
39. STEVENS RJ, KOTHARI V, ADLER AI, STRATTON IM, UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin. Sci. (2001) 101(6):671-679. Erratum in: Clin. Sci. (2002) 102(6):679.
40. CLARKE PM, GRAY AM, BRIGGS A et al.: A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia (2004) 47(10):1747-1759.
41. BROWN JB, PALMER AJ, BISGAARD P, CHAN W, PEDULA K, RUSSELL A: The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res. Clin. Pract. (2000) 50(Suppl. 3):S57-S64.
42. AMERICAN DIABETES ASSOCIATION CONSENSUS PANEL: Guidelines for computer modeling of diabetes and its complications. Diabetes Care (2004) 27(9):2262-2265.
43. PALMER AJ, ROZE S, VALENTINE WJ et al.: Validation of the CORE Diabetes Model Against Epidemiological and Clinical Studies. Curr. Med. Res. Opin. (2004) 20(Suppl. 8):27-40.
44. CLARKE P, GRAY A, ADLER A et al.: UKPDS Group. United Kingdom Prospective Diabetes Study. Cost-effectiveness analysis of intensive blood-glucose control with merformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia (2001) 44(3):298-304.
45. PALMER AJ, ROZE S, LAMMERT M et al.: Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the core diabetes model in type 2 diabetes. Curr. Med. Res. Opin. (2004) 20(Suppl. 8):41-51.
46. PALMER AJ, ROZE S, VALENTINE WJ et al.: Impact of changes in HbA(1c), lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE diabetes model. Curr. Med. Res. Opin. (2004) 20(Suppl. 8):53-58.